The global anatomic pathology testing market was valued at more than USD 8 billion in 2016 and is expected to reach almost USD 12 billion by 2021, says Technavio.
Technavio has announced its latest market research report on the global anatomic pathology testing market, under its in-vitro diagnostics portfolio. This market analysis discusses the major drivers and key emerging trends and offers an analysis of key vendors like Abbott Diagnostics, Agilent Technologies, Danaher, Roche Diagnostics, and Thermo Fisher Scientific.
According to Barath Palada, a lead analyst for in-vitro diagnostics research at Technavio, “Many pharmaceutical companies are shifting to personalized medicine and offer incentives for cancer therapies to cater to the rising demand. Personalizing of these treatments will enable better channeling of patient diagnostic information and communication of results to clinicians.”
Personalized medicine has high demand in the oncology therapeutic area. It involves better patient management and enables individualized treatment through diagnostic tests for real-time and rapid results. Roche Diagnostics, for instance, identifies defective proteins and genes extracted from tissues and developed advanced companion diagnostics to target individuals that respond to specific treatments.
Click here to request a free sample of this report
Presence of venture capitalists in the market
The presence of venture capitalists in the market has increased the financial flow support from venture capitalists, which is accelerating the development of anatomic pathology testing market. Venture capitals invest in start-ups through private equity funds, hedge funds, royalty funds, and other investments, thereby helping new entrants penetrate the market space and gain market shares.
Ready-to-use reagents
Ready-to-use reagents help minimize calculation, dilution, and pipetting errors, reduce the duration of the diagnostic procedure, and prevent contamination of samples. For instance, researchers used to mix different samples to form a reagent preparation for the diagnosis of breast cancer. The launch of HER2 IQFISH pharmDx by Agilent Technologies helped researchers to use ready-to-use reagents for the identification of breast cancer. Further emphasis on disease prevention and focus on accurate results will lead many medical facilities to use ready-to-use reagents for diagnostic purposes.
Ask an analyst to know more about this report
This research report includes an in-depth analysis and market shares and sizes of the sub-segments and geography. An analysis of the key companies, including their market shares, business overview, key financials, etc. is provided in this study. This market study also provides a detailed analysis of key drivers, challenges, and opportunities influencing this market.
A more detailed analysis is available in the Technavio report titled, ‘Global Anatomic Pathology Testing Market 2017-2021’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Clinical Reference Laboratory Services Market 2016-2020
- Global Genomics Biomarkers Market 2017-2021
- Global MRSA Testing Market 2017-2021
To read more press releases – click here
